drugset / Trial / NCT00036374

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis

NCT00036374 ↗

Phase 3 Completed 123 enrolled Centocor, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Juvenile Rheumatoid Arthritis (JRA).

Timeline

Start
2001-10
Primary completion
—
Completion
2006-12

Outcome

Missed primary endpoint

paper the between-group difference in this primary efficacy end point was not statistically significant (P = 0.12). PMID 17763439 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 3 mg/kg —
Subject Infliximab Monoclonal antibody 6 mg/kg —